AbbVie Inc. is 206.5x more valuable than Mineralys Therapeutics, Inc. by market capitalization ($402.35 B vs $1.95 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MLYS | ABBV |
|---|---|---|
| Market cap | $1.95 B | $402.35 B |
| US-listed rank | #2128 | #31 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$154.65M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 95.2 |
| SEC filings | 350 | 1,008 |
AbbVie Inc. is 206.5x more valuable than Mineralys Therapeutics, Inc. by market capitalization ($402.35 B vs $1.95 B).
Full pages: Mineralys Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.